ClinicalTrials.gg
CompletedNCT03495414Updated Apr 6, 2022

Neurobiological Underpinnings to Hypersexual Disorder

An observational study in Hypersexuality, Hypersexual Disorder and Compulsive Sexual Behavior, sponsored by Karolinska Institutet. Completed at 1 site in Sweden. Open to male participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-06.

Sponsored by Karolinska Institutet · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
42
Ages
18 Years to 100 Years
Sex
Male
01

Study summary

Hypersexual Disorder (HD), sometimes called "sexual addiction", is a disorder with intense sexual desires and psychological preoccupations that lead to out-of-control sexual activities with severe consequences. HD is related to higher risks of HIV infection and an important risk factor for committing sexual crimes. The prevalence of HD is 3-6% of the general population, thus, a significant burden for society. The neurobiological mechanisms behind HD are still unknown, and there is still a great need for causal treatments.

This study is aimed at identifying neurobiological and psychological mechanisms underlying HD as a basis for treatment development. The overall goal is to improve mental health, quality of life, diagnosis and treatment options for affected individuals, and to reduce the impact HD can have on society. Patients with HD will be recruited at Karolinska University Hospital in close collaboration between endocrinologists, psychologists, psychiatrists, and brain researchers at Karolinska Institutet. Cases and healthy controls will undergo brain scans (MRI), psychological and blood tests to quantify neurobiological, cognitive, and behavioral aspects of HD.

This study is directly integrated into clinical practice, can identify important targets for interventions and factors predicting treatment outcomes. This study is essential for a better understanding of HD, the improvement of treatments, and can have significant impact on the prevention of HIV infections and sexual crimes.

02

Conditions studied

  • Hypersexuality
  • Hypersexual Disorder
  • Compulsive Sexual Behavior
03

In context

Compulsive Sexual Behavior Disorder

22 studies on the registry are indexed under Compulsive Sexual Behavior Disorder; 8 are open to participants now.

Browse Compulsive Sexual Behavior Disorder studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,148 studies on the registry; 276 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients will be recruited through an ongoing CBT study (KAFKA_IT) at Karolinska University Hospital (ANOVA). Initial contact between patients and study coordinators will primarily be made through the phone helpline PrevenTell, designed to prevent sexual offences by targeting persons at risk. At the clinical visit patients will be evaluated in a face to face interview by trained psychologists/psychiatrists to establish psychiatric diagnoses, including the diagnosis of HD. If criteria for HD are met, patients will be informed about the present imaging study. Healthy controls from the Stockholm catchment area will be recruited through Karolinska Trial Alliance, and/or public advertisement in form of posters, online job postings and/or social media.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male
  • At least 18 years of age,
  • Fluent in the Swedish language
  • Patients will meet diagnostic criteria for hypersexual disorder and will not have started with any psychotherapy or psychological treatment.
  • Controls will be physically and psychologically healthy, and show no indication of clinical hypersexuality

Exclusion criteria

Exclusion Criteria:

For both patients and controls any reported medical or clinical condition known to affect brain structure and function, test performance, or associated with risks for the MRI environment will be exclusionary. The investigators will exclude for the following:

  • Severe neurological/psychiatric diseases or conditions (e.g., major depression, bipolar disorder, ADHD, autism, anxiety/panic disorder, obsessive compulsive disorder, personality disorder, Parkinson's disease, epilepsy, PTSD/chronic stress/burnout syndrom, Alzheimer's disease)
  • Gender identity disorder/gender dysphoria
  • Chronic pain conditions
  • Impared vision, or other vision problems that cannot be corrected with MR-safe equipment.
  • Hearing impairments, or problems with other senses
  • History of severe brain damage/injuries
  • Claustrophobia
  • Having metal implants, a pacemaker, metallic braces or other MRI
  • Alcohol/drug dependence/abuse, eating disorder, pathological gambling, during the past 6 months.
  • and /B, if the condition is untreated or virus levels detectable.
  • Untreated endocrinologic diseases
  • Medication: bensodiazepine, antipsychotics, mood stabilizers, centrally acting sympathicomimetics, SSRI (if use started less than 3 months ago). Any medication or pharmaceutical drug that interferes with sex hormone production or metabolism, i.e. ketoconazol, cyproteronacetate, spironolactone and similar drugs.

Note: There is a potentially higher prevalence of comorbidities and medication use in patients. To facilitate recruitment and study completion, the investigators may include subjects that report specific conditions at the discretion of the principle investigator. In those cases, corresponding information will be recorded in order to control for potential confounders.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
42 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Healthy Controls (HC)

    Controls will be physically and psychologically healthy and will show no indication of clinical hypersexuality.

    Other: Brain Imaging · Other: Cognitive testing · Other: Psychometric · Other: Blood test

  • Patients with hypersexual disorder (HD)

    Patients will meet diagnostic criteria for HD as defined in the DSM-5 proposed criteria for hypersexual disorder (Kafka, 2010) and CSBD according to ICD-11.

    Other: Brain Imaging · Other: Cognitive testing · Other: Psychometric · Other: Blood test

Interventions

  • OtherBrain Imaging

    * Structural MRI (T1 weighted) * Diffusion Tensor Imaging (DTI) * resting state functional MRI (rs-fMRI) * functional MRI (fMRI): Brain activity will be measured in response to sexual images (visually evoked sexual arousal; processing of sexual stimuli), and importantly during a phase when these stimuli are anticipated (neural correlates of wanting and desire; reward anticipation).

  • OtherCognitive testing

    We will administer neuropsychological tests assessing objective measures for * intelligence (Ravens Matrices) * impulsivity and risk-taking behavior (Balloon Analogue Risk Task) * inhibitory control (Stop Signal Task).

  • OtherPsychometric

    Administered questionnaires include anxiety and depression symptoms (MADRS, HADS, GAD), drug use (AUDIT, DUDIT), attention deficits (ASRS), impulsivity (BIS-11), reward seeking behavior (BIS/BAS), sexual orientation, (hyper)sexual behavior, desire and compulsivity aspects (HDSI, HBI, SCS, SDI, SIS/SES).

  • OtherBlood test

    Blood samples will be taken for routine health assessment, measurement of sex hormonal levels, HPA-axis function test (dexamethasone suppression), and potential DNA extraction and (epi)genetic profiling.

06

What researchers measure

Primary outcomes

  1. Brain activity

    Functional brain response (BOLD activity) upon presentation and anticipation of visual sexual stimuli.

    Time frame: acquired during brain imaging experiment (MRI scan day)

  2. Anatomical brain measures

    Measures for brain morphology (regional cortical volume, thickness, surface area, and subcortical volumes)

    Time frame: Acquired during brain imaging experiment (MRI scan day)

Secondary outcomes

  1. Resting state fMRI

    Functional connectivity

    Time frame: Acquired during fMRI experiment (MRI scan day)

  2. Diffusion MRI

    Structural connectivity

    Time frame: Acquired during fMRI experiment (MRI scan day)

  3. Reaction times

    Response reaction times during fMRI task

    Time frame: Acquired during fMRI experiment (MRI scan day)

  4. Raven Progressive Matrices (cognitive task)

    Objective measures for intelligence

    Time frame: Acquired at brain MRI assessment day, or as close to this day as possible.

  5. Balloon Analogue Risk Task (cognitive task)

    Objective measures for impulsivity/risk-taking

    Time frame: Acquired at brain MRI assessment day, or as close to this day as possible.

  6. Stop Signal Task (cognitive task)

    Objective measures for inhibitory control

    Time frame: Acquired at brain MRI assessment day, or as close to this day as possible.

  7. MADRS-S (questionnaire)

    Montgomery Asberg Depression Rating Scale

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  8. ASRS (questionnaire)

    Adult ADHD Self-Report Scale

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  9. AUDIT (questionnaire)

    Alcohol Use Disorders Identification Test

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  10. DUDIT (questionnaire)

    Drug Use Disorders Identification Test

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  11. EQ-5D (questionnaire)

    General Health information

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  12. 4-item Kinsey-scale (questionnaire)

    Sexual Orientation Dimension

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  13. HDSI (questionnaire)

    Hypersexual Disorder Screening Inventory

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  14. SCS (questionnaire)

    Sexual Compulsivity Scale

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  15. HBI (questionnaire)

    Hypersexual Behavior Inventory

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  16. SIS/SES (questionnaire)

    Sexual Inhibition/Excitation Scale

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  17. HADS (questionnaire)

    Hospital Anxiety and Depression Scale

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  18. GAD (questionnaire)

    General Anxiety Disorder scale

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  19. BRSI-SE (questionnaire)

    Bem Sex Role Inventory

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  20. RAADS (questionnaire)

    Ritvo Autism Asperger Diagnostic Scale

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  21. SDI (questionnaire)

    Sexual Desire Inventory

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  22. BIS-11 (questionnaire)

    Barratt Impulsiveness Scale

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  23. BIS/BAS (questionnaire)

    Behavioral Inhibition/Activation System

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  24. Sexual Behavior (questionnaire)

    Frequency of pornography consumption and sexual encounters.

    Time frame: Assessed through an online platform (as close to MRI scan day), and/or at MRI scan day

  25. fMRI experience rating (questionnaire)

    Ratings of emotions experienced in context of the fMRI task, incl. craving/desire, stimuli induced sexual arousal.

    Time frame: Assessed right before and after MRI scan

07

Study locations

1 site
  • Karolinska University Hospital (ANOVA)
    Stockholm, 113 64, Sweden
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Dec 2021, 44 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2018
First posted
Apr 12, 2018
StartActual
Apr 1, 2018
Primary completionActual
Dec 30, 2021
CompletionActual
Dec 30, 2021
Last update
Apr 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03495414
Collaborators
Karolinska University Hospital, ANOVA, Stockholm (Stefan Arver, Katarina Görts Öberg)
Responsible party
Christoph Abé (Assistant Professor, Karolinska Institutet) — Principal investigator
First posted
Apr 12, 2018
Start date
Apr 1, 2018
Primary completion
Dec 30, 2021
Completion
Dec 30, 2021
Last update
Apr 6, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion